Highest-materiality recent filing
Werewolf Therapeutics Q1 net loss $13.5M; sells JZP898 to Jazz and repays K2 debt
Cash and cash equivalents $46.5M as of March 31, 2026, vs $57.1M at Dec 31, 2025.
Werewolf Therapeutics announces strategic alternatives review; Q4 2025 net loss $8.4M
Engaged Piper Sandler as exclusive financial advisor to explore strategic alternatives including sale, merger, or asset sale.
Werewolf Therapeutics initiates strategic alternatives review, hires Piper Sandler
Feb 24, 2026: Werewolf (HOWL) announces exploration of strategic alternatives including sale, merger, or licensing.
Reduction in force affecting 64% of workforce; expected completion by Feb 13, 2026.
Werewolf Therapeutics receives Nasdaq deficiency notice for bid price below $1.00
Notice dated Feb 4, 2026: bid price closed below $1.00 for 30 consecutive business days.
WTX-124 monotherapy achieved 21% ORR in heavily pretreated advanced melanoma; 30% ORR in patients not primary resistant to prior immunotherapy.
Werewolf Therapeutics Q3 net loss $16.4M, cash $65.7M; key trial updates due Q4 2025
Cash and equivalents $65.7M as of Sept 30, 2025, expected to fund operations into Q4 2026.
Werewolf Therapeutics Q2 net loss $18M; WTX-124 data on track for Q4 2025
Cash $77.6M as of June 30, 2025, providing runway into Q4 2026.
Stock bid price closed below $1.00 for 30 consecutive business days, triggering Nasdaq deficiency notice.
Werewolf Therapeutics Q1 net loss $18.1M; cash $92M; WTX-124 data/FDA in H2 2025
Net loss of $18.1M in Q1 2025 vs $16.2M in Q1 2024; R&D spend $13.1M.
Werewolf Therapeutics reports Q4 2024 net loss of $20.4M; cash runway through Q2 2026
Cash and cash equivalents $111.0M at Dec 31, 2024; sufficient to fund operations through Q2 2026.
Werewolf Therapeutics reports Q3 net loss $16.7M; WTX-330 partial response in melanoma
Net loss $16.7M for Q3 2024 vs $8.3M in Q3 2023; cash $122.8M, runway through Q2 2026.
Werewolf Therapeutics Q2 2024 net loss $17.2M; positive clinical data for WTX-124 and WTX-330
Net loss of $17.2M in Q2 2024 vs $5.1M in Q2 2023; R&D expenses rose to $15.3M from $9.6M.
WTX-330 achieved 23-fold higher systemic IL-12 prodrug concentration vs rhIL-12 at 0.024 mg/kg; free IL-12 <1.6% of prodrug (cutoff June 12, 2024).
WTX-124 Phase 1/1b shows 3 objective responses (1 CR) in checkpoint-refractory solid tumors
3 objective responses out of 35 monotherapy-treated patients: 1 confirmed complete response, 2 partial responses.
Werewolf Therapeutics reports Q1 net loss of $16.2M; cash runway extended to Q1 2026
Net loss $16.2M in Q1 2024, up from $12.0M loss in Q1 2023; R&D expenses rose to $12.9M.
Werewolf Therapeutics reports Q4 2023 net loss $12M; CSO retiring March 29, 2024
Net loss of $12.0M in Q4 2023 ($37.4M full year) vs $11.9M in Q4 2022.
Werewolf Therapeutics outlines 2024 priorities: WTX-124/330 data, cash runway through Q1 2025
WTX-124: updated monotherapy and initial combo data expected in 1H 2024; RDE selection and dose expansion planned.
Werewolf Therapeutics appoints Dr. Michael B. Atkins, cancer immunotherapy expert, to board
Dr. Atkins appointed as Class III director effective Jan. 4, 2024; will serve until 2024 annual meeting.
Werewolf Therapeutics Q3 net loss $8.3M; WTX-124 shows early antitumor activity
Cash $130.1M as of Sep 30; sufficient to fund operations through Q4 2024.
16 heavily pretreated patients in first four monotherapy dose cohorts (1-12 mg); no dose-limiting toxicities or VLS observed.
Net loss $5.1M ($0.16/diluted share) vs $14.6M ($0.83) in Q2 2022; collaboration revenue $8.1M (up from $4.1M).
Werewolf Therapeutics Q1 net loss $12.0M; COO retiring; WTX-124 data expected 4Q23
Net loss of $12.0M improved from $15.3M in Q1 2022; cash and equivalents $147.9M.
Werewolf Therapeutics reports Q4 2022 net loss $11.9M; cash runway extended through Q4 2024
Net loss $11.9M for Q4 2022, compared to $17.9M in Q4 2021; full year net loss $53.8M (2021: $50.0M).
Net loss of $14.6M in Q2 2022, vs $10.9M in Q2 2021; R&D expenses rose to $13.9M.
Werewolf Therapeutics Q1 net loss $15.3M; Jazz Pharma license and $40M loan extend runway
Net loss of $15.3M in Q1 2022 vs. $7.4M year-ago; R&D expense rose to $10.9M from $4.8M.
Werewolf Therapeutics secures $40M loan facility; director resigns
Up to $40M term loan from Pacific Western Bank: $20M available immediately, $20M contingent on FDA acceptance of two INDs by March 2023.
Werewolf Therapeutics enters $15M upfront license deal with Jazz for WTX-613 (IFNα INDUKINE)
Upfront payment of $15M within 10 days of signing; Jazz to reimburse pre-clinical costs.
Werewolf Therapeutics reports 2021 net loss $50M, cash $157.5M; IND filings on track
Net loss $17.9M in Q4 2021 ($7.4M Q4 2020); full-year loss $50.0M ($15.0M 2020).
Werewolf Therapeutics reports Q2 2021 net loss $10.9M; cash of $183.2M after IPO
Completed May 2021 IPO: 7.5M shares at $16.00, net proceeds $109.2M.
On February 19, 2025, Derek DiRocco, M.D., notified Werewolf Therapeutics, Inc. (the “Company”) of his intent to resign from the Board of Directors (the “Board”) of the Company, effective upon the Company’s 2025 annual meeting of stockholders.
On February 19, 2025, the Board of the Company, upon recommendation of the Board’s Nominating and Corporate Governance Committee, appointed Anil Singhal, Ph.D., as a director.
On March 3, 2024, Cynthia Seidel-Dugan, Ph.D., notified the Company of her intent to retire from her position as Chief Scientific Officer of the Company, effective as of March 29, 2024.
On January 4, 2024, the Board of Directors (the “Board”) of Werewolf Therapeutics, Inc. (the “Company”), upon recommendation of the Board’s Nominating and Corporate Governance Committee, appointed Michael B. Atkins, M.D., as a director.
On April 12, 2022, Sakae Asanuma submitted his resignation from the Board of Directors of the Company effective as of April 15, 2022.
On October 28, 2021, the Board of Directors (the “Board”) of Werewolf Therapeutics, Inc. (the “Company”), upon recommendation of the Board’s Nominating and Corporate Governance Committee, appointed Meeta Chatterjee, Ph.D., as a director.
Max materiality 0.80 · Median 0.60 · Most common event earnings